Jun 14, 2022 / 09:40PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Welcome. We're really pleased to have, as our next company, participating in the Goldman Sachs Healthcare Conference, Entrada Therapeutics. My name is Chris Shibutani, and along with my esteemed cum logical, well-organized associate colleague, Stephen Sloan. We are very pleased to be having a discussion with the management team, CEO, Dipal Doshi; as well as Natarajan Sethuraman, the Chief Scientific Officer.
Welcome and thank you so much for making this trip. We would really appreciate this opportunity and look forward to really creating more content and substance to help people familiarize with the company, the platform, the scope of opportunities and really be thoughtful about developing that further here so that people can understand. So perhaps a quick overview Dipal.
Dipal Doshi - Entrada Therapeutics, Inc. - President, CEO & Director
And thank you, Chris. Thank you, Steve. Thanks for the Goldman team for having us here. It's always nice to be kind of in person.
Entrada Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers